{"id":63112,"date":"2026-05-15T22:03:17","date_gmt":"2026-05-15T20:03:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/"},"modified":"2026-05-15T22:03:17","modified_gmt":"2026-05-15T20:03:17","slug":"emmaus-life-sciences-reports-quarterly-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/","title":{"rendered":"Emmaus Life Sciences Reports Quarterly Financial Results"},"content":{"rendered":"
\n

TORRANCE, Calif.–(BUSINESS WIRE)–Emmaus Life Sciences, Inc. (OTCQB: EMMA)<\/b>, <\/b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026.<\/p>\n

\nHighlights<\/b><\/p>\n

\n\u201cWe realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, or MENA, region,\u201d commented Willis Lee, Chairman and Chief Executive Officer of Emmaus. \u201cOur loss from operations improved by 16% year-over-year, reflecting the impact of our cost reduction initiatives,\u201d he added.<\/p>\n

\nFinancial and Operating Results<\/b><\/p>\n

\nNet Revenues. <\/b>Net revenues for the three months ended March 31, 2026 were $2.0 million, compared to $2.4 million in the same period in 2025. The decrease was due to a decrease in U.S. sales which management attributes to competition from the generic version of L-Glutamine introduced in the market in mid-2024, partially offset by an increase of sales in the MENA region.<\/p>\n

\nOperating Expenses<\/b>. Total operating expenses for the three months were $2.6 million compared to $3.2 million in the comparable period in 2025. The decrease was due primarily to decreases in research and development expenses and general and administrative expenses attributable to a reduction in headcount and other cost cutting measures initiated in the second half of 2024.<\/p>\n

\nLoss From Operations.<\/b> Loss from operations for the three months was $0.8 million compared to $1.0 million in the same period in 2025. This was due to the decrease in net revenues, which was more than offset by lower operating expenses.<\/p>\n

\nOther Expense. <\/b>The company realized other expense of $2.3 million for the three months compared to $1.3 million in the same period in 2025. The increase was primarily due to increases in interest expense and change in fair value of conversion feature derivative.<\/p>\n

\nNet Loss<\/b>. For the three months, the company realized a net loss of $3.3 million, or $0.05 basic earnings per share based on approximately 70.2 million weighted-average common shares, compared to net loss of $2.3 million, or $0.04 basic earnings per share based on approximately 63.9 million weighted-average common shares in the comparable period in 2025. The increase in net loss was attributable primarily to the increase in other expense.<\/p>\n

\nLiquidity and Capital Resources<\/b>. At March 31, 2026, the company had cash and cash equivalents of $1.1 million, compared to $2.1 million at December 31, 2025.<\/p>\n

\nAbout Emmaus Life Sciences<\/b><\/p>\n

\nEmmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari\u00ae<\/sup> (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus\u2019 application for marketing authorization is awaiting final action by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com<\/a>.<\/p>\n

\nAbout Endari\u00ae<\/sup><\/b> (prescription grade L-glutamine oral powder)<\/p>\n

\nEndari\u00ae<\/sup>, Emmaus\u2019 prescription grade L-glutamine oral powder, was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older.<\/p>\n

\nIndication<\/b><\/p>\n

\nEndari\u00ae<\/sup> is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.<\/p>\n

\nImportant Safety Information<\/b><\/p>\n

\nThe most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.<\/p>\n

\nAdverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.<\/p>\n

\nThe safety and efficacy of Endari\u00ae<\/sup> in pediatric patients with sickle cell disease younger than five years of age has not been established.<\/p>\n

\nFor more information, please see full Prescribing Information of Endari\u00ae<\/sup> at: www.ENDARIrx.com\/PI<\/a>.<\/p>\n

\nAbout Sickle Cell Disease<\/b><\/p>\n

\nThere are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.1<\/sup> The genetic mutation responsible for SCD causes an individual’s red blood cells to distort into a “C” or a sickle shape, reducing their ability to transport oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together, which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads to physical symptoms of incapacitating pain, tissue and organ damage, and early death.2<\/sup><\/p>\n

\n1<\/sup>Source: Data & Statistics on Sickle Cell Disease \u2013 National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, December 2020.<\/p>\n

\n2<\/sup>Source: Committee on Addressing Sickle Cell Disease \u2013 A Strategic Plan and Blueprint for Action — National Academy of Sciences Press, 2020.<\/p>\n

\nForward-looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including doubt about the company\u2019s ability to continue as a going concern and other factors disclosed in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 31, 2026 and Quarterly Report on Form 10-Q filed on May 15, 2026, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0Emmaus Life Sciences, Inc.<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nCondensed Consolidated Statement of Operations and Comprehensive Income (Loss)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\n(In thousands, except share and per share amounts)<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

\nThree Months Ended March 31,<\/b><\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

\n2026<\/b><\/p>\n<\/td>\n

<\/td>\n\n

\n2025<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nRevenue, Net<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n1,982<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n2,406<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nCost of Goods Sold<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n168<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n225<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nGross Profit<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n1,814<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2,181<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating Expenses<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2,637<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n3,161<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nIncome (Loss) from Operations<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(823<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(980<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet Loss<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(3,335<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(2,330<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n<\/tr>\n

\n

\nComprehensive Loss<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(4,253<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(2,132<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet Loss per Share<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(0.05<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(0.04<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n<\/tr>\n

\n

\nWeighted Average Common Shares Outstanding<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n70,188,263<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n63,865,571<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nEmmaus Life Sciences, Inc.<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nCondensed Consolidated Balance Sheets<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\n(In thousands)<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

\nAs of<\/b><\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

\nMarch 31, 2026<\/b><\/p>\n<\/td>\n

<\/td>\n\n

\nDecember 31, 2025<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nAssets<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nCurrent Assets:<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nCash and cash equivalents<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n1,072<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n2,127<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nAccounts receivable, net<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2,048<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2,804<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nInventories, net<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n1,909<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n1,555<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nPrepaid expenses and other current assets<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n966<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n1,260<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Current Assets<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n5,995<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n7,746<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nProperty and Equipment, net<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n98<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n113<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nRight of use assets<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n736<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n766<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nInvestment in convertible bond<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n11,664<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n12,604<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther Assets<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n203<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n207<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Assets<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n18,696<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n21,436<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\nLiabilities and Stockholders\u2019 Deficit<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nCurrent Liabilities:<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nAccounts payable and accrued expenses<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n24,487<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n22,615<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating lease liabilities, current portion<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n349<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n348<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nConversion feature derivative, notes payable<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n235<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n–<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nNotes payable, current portion<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n10,696<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n11,151<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nConvertible notes payable, net of discount<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n17,356<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n17,380<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther current liabilities<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n17,458<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n17,578<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Current Liabilities<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n70,581<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n69,072<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther long-term liabilities<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n15,975<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n15,972<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Liabilities<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n86,556<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n85,044<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nStockholders\u2019 Deficit<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(67,860<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(63,608<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Liabilities & Stockholders\u2019 Deficit<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n18,696<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n21,436<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u00a0<\/p>\n

Contacts<\/b> <\/p>\n

\nCompany Contact:<\/b>
Emmaus Life Sciences, Inc.
\n
Investor Relations
\n
(310) 214-0065
\n
IR@emmauslifesciences.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TORRANCE, Calif.–(BUSINESS WIRE)–Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. Highlights \u201cWe realized an 18% decline in net revenues for three month ended … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-63112","6":"format-standard","7":"category-industry"},"yoast_head":"\nEmmaus Life Sciences Reports Quarterly Financial Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emmaus Life Sciences Reports Quarterly Financial Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TORRANCE, Calif.–(BUSINESS WIRE)–Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. Highlights \u201cWe realized an 18% decline in net revenues for three month ended ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T20:03:17+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emmaus-life-sciences-reports-quarterly-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emmaus-life-sciences-reports-quarterly-financial-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Emmaus Life Sciences Reports Quarterly Financial Results\",\"datePublished\":\"2026-05-15T20:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emmaus-life-sciences-reports-quarterly-financial-results\\\/\"},\"wordCount\":1138,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emmaus-life-sciences-reports-quarterly-financial-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emmaus-life-sciences-reports-quarterly-financial-results\\\/\",\"name\":\"Emmaus Life Sciences Reports Quarterly Financial Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2026-05-15T20:03:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emmaus-life-sciences-reports-quarterly-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emmaus-life-sciences-reports-quarterly-financial-results\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emmaus-life-sciences-reports-quarterly-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emmaus Life Sciences Reports Quarterly Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emmaus Life Sciences Reports Quarterly Financial Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Emmaus Life Sciences Reports Quarterly Financial Results - Pharma Trend","og_description":"TORRANCE, Calif.–(BUSINESS WIRE)–Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. Highlights \u201cWe realized an 18% decline in net revenues for three month ended ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/","og_site_name":"Pharma Trend","article_published_time":"2026-05-15T20:03:17+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Emmaus Life Sciences Reports Quarterly Financial Results","datePublished":"2026-05-15T20:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/"},"wordCount":1138,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/","url":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/","name":"Emmaus Life Sciences Reports Quarterly Financial Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2026-05-15T20:03:17+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/emmaus-life-sciences-reports-quarterly-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Emmaus Life Sciences Reports Quarterly Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63112"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63112\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}